Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | CD69 | Q07108 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.32 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.32 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PYGB | P11216 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13655844 | 0.78 | ALDH1A1 (0.31) | ALDH1A1LGALS8LGALS3 | |
| SCHEMBL17117587 | 0.77 | OGA (0.38) | ALDH1A1THRBMAPK1CD69OGA | |
| SCHEMBL12936319 | 0.74 | ALDH1A1 (0.58) | ALDH1A1THRBMAPK1CD69OGA | |
| SCHEMBL17771655 | 0.74 | ALDH1A1 (0.58) | ALDH1A1THRBMAPK1CD69OGA | |
| SCHEMBL21452946 | 0.73 | ATM (0.39) | ALDH1A1SMN1; SMN2ASGR1 | |
| SCHEMBL14507147 | 0.72 | MAPK1 (0.43) | ALDH1A1THRBMAPK1CD69OGA | |
| SCHEMBL14507155 | 0.72 | ALDH1A1 (0.41) | ALDH1A1THRBMAPK1CD69OGA | |
| SCHEMBL22919274 | 0.71 | ALDH1A1 (0.49) | ALDH1A1THRBMAPK1CD69OGA | |
| SCHEMBL7154123 | 0.70 | MAPK1 (0.54) | ALDH1A1THRBMAPK1CD69OGA | |
| SCHEMBL14507148 | 0.70 | ALDH1A1 (0.45) | ALDH1A1THRBMAPK1CD69OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200254241-A1 | ELECTRICAL METHOD OF DELIVERING HYALURONIC ACID THROUGH THE SKIN | L'OREAL (FR) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200254241-A1 | ELECTRICAL METHOD OF DELIVERING HYALURONIC ACID THROUGH THE SKIN | CD44, CUTA, CD69 | ALDH1A1 3798/4885THRB 2784/4885MAPK1 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.